Cancer immunotherapy

Definition

Cancer immunotherapy is a therapy used to treat cancer patients that involves or uses components of the immune system. Some cancer immunotherapies consist of antibodies that bind to, and inhibit the function of, proteins expressed by cancer cells. Other cancer immunotherapies include vaccines and T cell infusions.

Featured

Latest Research and Reviews

  • Reviews |

    Chimeric antigen receptor (CAR)-T-cell therapies are showing great promise in the treatment of cancer, particularly B-cell malignancies, but are associated with characteristic, potentially fatal toxicities, principally cytokine-release syndrome, CAR-T-cell-related encephalopathy syndrome, and haemophagocytic lymphohistiocytosis/macrophage-activation syndrome. Herein, the CAR-T-cell-therapy-associated TOXicity (CARTOX) Working Group, comprising multidisciplinary investigators from various institutions with clinical experience in the use of a range of CAR-T-cell platforms, review these acute toxicities and provide monitoring, grading, and management recommendations.

    • Sattva S. Neelapu
    • , Sudhakar Tummala
    • , Partow Kebriaei
    • , William Wierda
    • , Cristina Gutierrez
    • , Frederick L. Locke
    • , Krishna V. Komanduri
    • , Yi Lin
    • , Nitin Jain
    • , Naval Daver
    • , Jason Westin
    • , Alison M. Gulbis
    • , Monica E. Loghin
    • , John F. de Groot
    • , Sherry Adkins
    • , Suzanne E. Davis
    • , Katayoun Rezvani
    • , Patrick Hwu
    •  & Elizabeth J. Shpall
  • Research | | open

    Bacterial outer membrane vesicles (OMVs) contain immunogens but no study has yet examined their potential in treating cancer. Here, the authors demonstrate that OMVs can suppress established tumours and prevent tumour metastasis by an interferon-γ mediated antitumor response.

    • Oh Youn Kim
    • , Hyun Taek Park
    • , Nhung Thi Hong Dinh
    • , Seng Jin Choi
    • , Jaewook Lee
    • , Ji Hyun Kim
    • , Seung-Woo Lee
    •  & Yong Song Gho
  • Research | | open

    The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.

    • N. Jacquelot
    • , M. P. Roberti
    • , D. P. Enot
    • , S. Rusakiewicz
    • , N. Ternès
    • , S. Jegou
    • , D. M. Woods
    • , A. L. Sodré
    • , M. Hansen
    • , Y. Meirow
    • , M. Sade-Feldman
    • , A. Burra
    • , S. S. Kwek
    • , C. Flament
    • , M. Messaoudene
    • , C. P. M. Duong
    • , L. Chen
    • , B. S. Kwon
    • , A. C. Anderson
    • , V. K. Kuchroo
    • , B. Weide
    • , F. Aubin
    • , C. Borg
    • , S. Dalle
    • , O. Beatrix
    • , M. Ayyoub
    • , B. Balme
    • , G. Tomasic
    • , A. M. Giacomo
    • , M. Maio
    • , D. Schadendorf
    • , I. Melero
    • , B. Dréno
    • , A. Khammari
    • , R. Dummer
    • , M. Levesque
    • , Y. Koguchi
    • , L. Fong
    • , M. Lotem
    • , M. Baniyash
    • , H. Schmidt
    • , I. M. Svane
    • , G. Kroemer
    • , A. Marabelle
    • , S. Michiels
    • , A. Cavalcanti
    • , M. J. Smyth
    • , J. S. Weber
    • , A. M. Eggermont
    •  & L. Zitvogel
  • Research | | open

    MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist immunotherapy resulting in synergic therapeutic effects.

    • Sathana Dushyanthen
    • , Zhi Ling Teo
    • , Franco Caramia
    • , Peter Savas
    • , Christopher P. Mintoff
    • , Balaji Virassamy
    • , Melissa A. Henderson
    • , Stephen J. Luen
    • , Mariam Mansour
    • , Michael H. Kershaw
    • , Joseph A. Trapani
    • , Paul J. Neeson
    • , Roberto Salgado
    • , Grant A. McArthur
    • , Justin M. Balko
    • , Paul A. Beavis
    • , Phillip K. Darcy
    •  & Sherene Loi

News and Comment